NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01149122,Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract Carcinoma,https://clinicaltrials.gov/study/NCT01149122,,COMPLETED,"The purpose of this study is to determine whether Gemcitabine/Oxaliplatin (GEMOX) with or without Erlotinib (Tarceva) is effective in the treatment of unresectable, metastatic biliary tract carcinoma.",NO,"Unresectable, Metastatic Biliary Tract Carcinoma",DRUG: Gemcitabine/Oxaliplatin|DRUG: Gemcitabine/Oxaliplatin with Erlotinib (Tarceva),"Progression Free Survival, every 6 weeks","Safety profile, 24 months|Response rate, 24 months|Duration of response, 24 months|Time to progression, 24 months|Overall survival, 24 months|Correlative analyses: EGFR mutation, EGFR amplification, akt expression, EGFR polymorphism analyses, 24 months",,Samsung Medical Center,,ALL,"ADULT, OLDER_ADULT",PHASE3,266,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-12-024,2009-01,2012-01,2012-06,2010-06-23,,2014-05-15,"Samsung Medical Center, Seoul, Korea, Republic of",
